Bristol Myers Squibb Co (CELG-RI) — 10-Q Filings

10-Q Filings (6)

• BMS Earnings Soar 82% on Growth Portfolio, Legacy Drugs Decline — Oct 30, 2025 Risk: medium
  Bristol-Myers Squibb Co. reported a significant increase in net earnings attributable to BMS, reaching $2.201 billion for the three months ended September 30, 2
• BMS Q2 Revenue Dips Amid Rising R&D Spend — Jul 31, 2025 Risk: medium
  Bristol Myers Squibb Co. reported total revenues of $11.45 billion for the three months ended June 30, 2025, a decrease from $11.70 billion in the same period o
• Bristol Myers Squibb Q1 2025 Update — Apr 24, 2025 Risk: medium
  Bristol Myers Squibb Co. reported its first quarter 2025 results, ending March 31, 2025. The company's filing details various financial components, including ne
• Bristol Myers Squibb Q3 Sales Dip Slightly — Oct 31, 2024 Risk: medium
  Bristol Myers Squibb Co. reported its third-quarter 2024 results for the period ending September 30, 2024. The company's net product sales for the third quarter
• Bristol Myers Squibb Q2 Sales Rise to $23.1B — Jul 26, 2024 Risk: low
  Bristol Myers Squibb Co. reported its Q2 2024 results for the period ending June 30, 2024. The company's net product sales for the first six months of 2024 were
• Bristol Myers Squibb Co. Files 10-Q for Period Ending March 31, 2024 — Apr 25, 2024 Risk: medium
  BRISTOL MYERS SQUIBB CO (CELG-RI) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Bristol Myers Squibb reported net product sales of $9,275 mill

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX